AZD6140: a promising new treatment for patients with acute coronary syndromes
This article has no abstract so we have provided the first paragraph of the full text.
Antiplatelet therapy is standard in most cases of ST-segment elevation and non-ST-segment elevation (NSTE) acute coronary syndromes (ACS). Aspirin and clopidogrel are both effective treatments, and a combination of these agents gives greater protection against arterial thromboembolic events than does either drug alone. Patients who do not respond well to clopidogrel might benefit from new drugs such as AZD6140, an oral P2Y12 receptor antagonist currently undergoing clinical trials.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
